Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Regeneron Pharmaceuticals
Study ID
NCT01688960
Phase
PHASE1
Status
Completed

Conditions

  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open-label, multicenter, ascending, multiple dose study of nesvacumab (REGN910/ SAR307746) in combination with aflibercept ("ziv-aflibercept" in the U.S.)

Key Dates

First listed
Sep 20, 2012
Start date
Oct 31, 2012
Status verified
Mar 2015
Primary completion
Nov 30, 2014
Completion
Nov 30, 2014

Study Design

Enrollment
48 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1
  • Experimental: Cohort 2
  • Experimental: Cohort 3a
  • Experimental: Cohort 3b
  • Experimental: Cohort 4

Primary Outcome Measure

Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D) [ Time Frame: Day 1 to Day 28 ]

Locations (5)

FacilityCityStateZIPSite coordinators
-IndianapolisIndiana--
-New YorkNew York--
-Oklahoma CityOklahoma--
-PhiladelphiaPennsylvania--
-San AntonioTexas--

Related Studies